dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
Published 5 years ago • 382 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
2:05
danny rischin, md, mbbs, fracp, shares thoughts on keynote-048 presented at asco 2019
-
5:48
the impact of systemic therapy and keynote-048 trial
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
9:31
study in patients with recurrent ir metastatic head & neck squamous cell carcinoma
-
1:55
dr. burtness on findings of keynote-048 in head and neck cancer
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
7:56
keynote-048: progression post next line for r/m hnscc
-
26:25
practice changing trials of immunotherapy in head and neck cancer - prof danny rischin
-
1:06
dr. cohen discusses the keynote-040 trial in head and neck cancer
-
1:09
the future role of immunotherapy in head and neck cancers
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
1:18
keynote-048 trial
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
4:32
biology of head and neck squamous cell cancer (hnscc)
-
1:41
dr. bauml on keynote-055 study for patients with hnscc
-
6:51
pembrolizumab and nivolumab in recurrent hnscc